Key Points
- Major shareholder Francisco Trust Under Agreemen sold 41,143 shares of Dyadic International at $1.84 each, totaling about $75,703, which reduced its stake by 1.18%.
- Dyadic International shares were reported up 5.3% and opened at $1.02, with the company valued at about $37.13 million and carrying a high debt-to-equity ratio of 4.08.
- The biotech company recently posted a Q1 loss of $0.05 per share, missing estimates, though revenue of $1.11 million came in above expectations; analysts currently have a Hold rating consensus with a $3.00 target price.
Dyadic International Inc. (NASDAQ:DYAI - Get Free Report) major shareholder Francisco Trust Under Agreemen sold 15,000 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $2.01, for a total transaction of $30,150.00. Following the sale, the insider directly owned 3,375,664 shares in the company, valued at $6,785,084.64. The trade was a 0.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Dyadic International Trading Up 10.1%
Shares of NASDAQ DYAI opened at $1.06 on Tuesday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. Dyadic International Inc. has a 52-week low of $0.65 and a 52-week high of $1.35. The firm has a 50 day moving average price of $0.77 and a two-hundred day moving average price of $0.83. The stock has a market cap of $38.81 million, a P/E ratio of -4.70 and a beta of 1.15.
Dyadic International (NASDAQ:DYAI - Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The business had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. As a group, equities analysts forecast that Dyadic International Inc. will post 0.13 EPS for the current year.
Institutional Trading of Dyadic International
A number of institutional investors have recently bought and sold shares of DYAI. Geode Capital Management LLC grew its holdings in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company's stock worth $284,000 after acquiring an additional 36,266 shares during the period. Marathon Capital Management lifted its stake in shares of Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 50,000 shares during the period. Apis Capital Advisors LLC acquired a new position in shares of Dyadic International in the 3rd quarter valued at about $1,817,000. Landscape Capital Management L.L.C. bought a new stake in shares of Dyadic International during the 3rd quarter valued at about $190,000. Finally, Bank of America Corp DE boosted its position in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 26,965 shares in the last quarter. Institutional investors own 27.95% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Dyadic International in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Dyadic International currently has an average rating of "Hold" and an average target price of $3.00.
Read Our Latest Stock Report on Dyadic International
Trending Headlines about Dyadic International
Here are the key news stories impacting Dyadic International this week:
- Positive Sentiment: Dyadic said global collaborations continue to validate its C1 protein-expression platform and expand its commercial opportunity, reinforcing the investment case around its core biotechnology technology. Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential
- Neutral Sentiment: The company’s latest reported quarterly results were mixed, with revenue beating expectations but earnings per share missing estimates, leaving investors focused on future commercialization progress rather than near-term profitability.
- Negative Sentiment: Major shareholder Francisco Trust Under Agreemen disclosed additional stock sales, adding to recent insider selling that may create some caution around the stock’s near-term momentum.
Dyadic International Company Profile
(
Get Free Report)
Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company's core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.
The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
